Disopyramide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Disopyramide and local guidelines before prescribing.
Class Ia antiarrhythmic
Mechanism
Class Ia sodium-channel blocker with anticholinergic effect.
Uses
Ventricular arrhythmias, vagally mediated AF.
Dosing
- Disopyramide | Obstructive HCM (specialist): 100 mg three to four times daily; total 400–600 mg daily; monitor QTc and anticholinergic effects.
Cardiology: Cardiomyopathies
Side effects
Dry mouth, urinary retention, constipation, hypotension, QT prolongation, heart failure.
Interactions
QT-prolonging drugs; beta-blockers; clarithromycin.
Contraindications and cautions
Heart block, heart failure, glaucoma
Monitoring
ECG, BP
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose in renal and hepatic impairment
Overdose and reversal
Supportive
Special advice
Avoid in heart failure; anticholinergic effects limit use in older men.
More from the textbook: uses, cautions and other points
- Second-line: Add disopyramide (negative inotrope; QT and anticholinergic monitoring) or mavacamten , a cardiac myosin inhibitor (NICE TA913: add-on for symptomatic NYHA II–III obstructive HCM).
Cardiology: Cardiomyopathies - Obstructive HCM: Beta blocker or verapamil/diltiazem, then disopyramide or mavacamten; avoid vasodilators and over-diuresis.
Cardiology: Cardiomyopathies - ⚠️ Prescribing note: These are examples, not automatic prescriptions. Review contraindications, interactions, pregnancy, renal function and specialist advice - particularly for disopyramide, mavacamten, amiodarone and amyloid disease-modifying drugs.
Cardiology: Cardiomyopathies - Ia | Sodium channel block, prolong repolarisation - quinidine, procainamide, disopyramide | Rarely used; QT prolongation
Cardiology: Anatomy Physiology and Pharmacology - Disopyramide: QTc, urinary retention, glaucoma, dry mouth; may need pyridostigmine for anticholinergic effects.
Cardiology: Cardiomyopathies
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (1 mention)
- Cardiology: Cardiomyopathies (5 mentions)
- Integrated cardiology chapter (5 mentions)